Eli Lilly Announces $6.5 Billion Texas Manufacturing Plant for Weight-Loss Pill

Eli Lilly (LLY) is investing $6.5 billion in a state-of-the-art pharmaceutical manufacturing facility in Houston, Texas. The plant will primarily produce the company's highly anticipated weight-loss pill, Orforglipron, slated for global launch in 2026 pending regulatory approval.

The Texas facility represents part of Eli Lilly's broader $27 billion U.S. expansion plan, which includes four new manufacturing sites. This follows $23 billion in domestic investments since 2020 as pharmaceutical companies brace for potential import tariffs under the TRUMP administration.

Analysts highlight production capacity as critical for Eli Lilly to maintain dominance in the lucrative weight-loss drug market. Two additional U.S. manufacturing locations will be announced before year-end.